Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach
Background Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a pandemic by the World Health Organization, and the identification of effective therapeutic strategy is a need of the hour to combat SARS-CoV-2 infection. In this...
Main Authors: | Tamizhini Loganathan, Srimathy Ramachandran, Prakash Shankaran, Devipriya Nagarajan, Suma Mohan S |
---|---|
Format: | Article |
Language: | English |
Published: |
PeerJ Inc.
2020-06-01
|
Series: | PeerJ |
Subjects: | |
Online Access: | https://peerj.com/articles/9357.pdf |
Similar Items
-
Identification of 37 Heterogeneous Drug Candidates for Treatment of COVID-19 via a Rational Transcriptomics-Based Drug Repurposing Approach
by: Andrea Gelemanović, et al.
Published: (2021-01-01) -
Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review
by: Bruno Silva Andrade, et al.
Published: (2020-12-01) -
Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics
by: Dan-Yang Liu, et al.
Published: (2021-04-01) -
A Rapid Strategy for Repurposing Drugs for COVID-19
by: Maryam Khoubnasabjafari, et al.
Published: (2020-11-01) -
SARS-CoV-2: Virology and Drug Repurposing Approaches
by: Ratika Rahmasari, et al.
Published: (2020-07-01)